0000950103-15-009748.txt : 20151228 0000950103-15-009748.hdr.sgml : 20151225 20151228124052 ACCESSION NUMBER: 0000950103-15-009748 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20151228 DATE AS OF CHANGE: 20151228 EFFECTIVENESS DATE: 20151228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZS Pharma, Inc. CENTRAL INDEX KEY: 0001459266 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263305698 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-36489 FILM NUMBER: 151308552 BUSINESS ADDRESS: STREET 1: 508 WRANGLER DRIVE, SUITE 100 CITY: COPPELL STATE: TX ZIP: 75019 BUSINESS PHONE: 650-458-4100 MAIL ADDRESS: STREET 1: 508 WRANGLER DRIVE, SUITE 100 CITY: COPPELL STATE: TX ZIP: 75019 15-12B 1 dp62020_1512b.htm FORM 15-12B

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF
THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER
SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-36489

ZS Pharma, Inc.

(Exact name of registrant as specified in its charter)

1100 Park Place, Suite 300
San Mateo, California
(650) 458-4100

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.001 per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)		x
Rule 12g-4(a)(2)		o
Rule 12h-3(b)(1)(i)		x
Rule 12h-3(b)(1)(ii)		o
Rule 15d-6		o

Approximate number of holders of record as of the certification or notice date: 1

Pursuant to the requirements of the Securities Exchange Act of 1934, ZS Pharma, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

ZS PHARMA, INC.


By:	/s/ Mark Asbury
	Name:	Mark Asbury
	Title:	Chief Legal Officer & General Counsel

Date: December 28, 2015